AAVantgarde Bio: Valuation, Funding & Investors
https://www.aavantgarde.com/Therapeutics
A clinical-stage biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases. The company's lead programs target Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B, two severe, inherited retinal diseases with no approved treatments.
Leadership & Board
- Current Number of Employees
- 76
- Current LinkedIn Followers
- 8,040
Latest Estimated Valuation
- Total Amount Raised
- $206M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $141M
- Latest Funding Round
- Series B
Employee Trend
AAVantgarde Bio had 76 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
76Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
AAVantgarde Bio had 8,040 followers as of November 9, 2026. The number of followers increased by 25 (0.31%) week-over-week.
8,040Latest Followers Count
25(0.31%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 03, 2025 | Series B | $141.00M | ― |
| Jul 06, 2023 | Series A | $65.30M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Schroders Capital | Series B |
| Forbion | Series B |
| Atlas Venture | Series B |
| Longwood Fund | Series B |
| Sofinnova Partners | Series B |
| Sixty Degree Capital | Series B |
| Amgen Ventures | Series B |
| XGEN Venture | Series B |
Similar Companies
A snapshot of private companies similar to AAVantgarde Bio, helping you discover and navigate related company profiles.
Related News and Analysis
